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LETTER FROM THE EDITORS
Welcome to the Spring 2013 volume of the Health Law & Policy Brief In this issue, we reflect on the
rapidly evolving regulatory framework in both the healthcare and pharmaceutical industries, as well as
examine a number of public policy concerns related to maintaining health for our nation's citizens.
As the United States witnesses the cavalier march of healthcare costs to levels previously unseen, both
political and industry leaders are looking for innovative ways to contain those costs and reverse this troubling
course. In the delivery of healthcare services, the emphasis is on better care coordination, enhanced
communication between providers, and value-based purchasing by the federal government. Likewise, the
pharmaceutical industry is dealing with an ongoing struggle between brand-name and generic drugs, as the
government attempts to encourage research and development by brand-name manufacturers while reducing
often exorbitant drug costs through generic substitution. Adding to the complexity of the pharmaceutical
industry is the unique role of biologics and their sensitive manufacturing processes, as well as the recently
implemented Physician Payment Sunshine Act, which requires drug manufacturers to report payments to
physicians in an effort to increase transparency in the sector.
Consequently, the time is ripe for law and public policy students and practioners alike to engage in critical
analyses of our current healthcare regime and develop creative solutions to some of these pressing problems.
It will take the collective effort of many minds to develop real, long-lasting, and workable routes toward
correcting the U.S. healthcare system. The pages that follow represent but a small sliver of the intensive
thought these matters will require.
On behalf of the Health Law & Policy Brief Editorial Board, we would like to specially thank our staff
members, whose tireless effort toward reviewing and editing these pieces ensures that we continually
produce relevant, high-quality articles on health law issues. This volume would not be possible without
their hard work and dedication. For questions or information about the Health Law & Policy Brief please
visit our new website at www.healthlawpolicy.org.
Best,
Jake & Katherine
Ill
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